EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune Checkpoint Inhibitor Myocarditis and Myotoxicity

Joe-Elie Salem iD

Circulation · 01.09.2026 · 154 (9) · 863-871

DOI: 10.1161/circulationaha.126.081201 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 01.09.2026. Verfasst von Joe-Elie Salem. Beteiligte Einrichtung: Sorbonne Université, INSERM, Department of Pharmacology, CIC-2503, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI)–associated myocarditis is uncommon but has been described as an important and potentially fatal complication of cancer treatment. Increasing evidence from a variety of data sources have reframed this complication as part of ICI-associated myotoxicity (ICI-M), a systemic cardiomuscular syndrome in which myocarditis, myositis, conduction disease, ventricular arrhythmias, dysphagia, pseudo-myasthenic oculobulbar signs, and respiratory muscle failure may coexist. Elevated troponin with ICI use is not synonymous with myocarditis but instead should trigger a structured evaluation that considers symptoms, ECG findings, troponin and creatine kinase concentrations, structural and functional assessments including left ventricular function, pathology when feasible, and exclusion of alternative causes including other cardiotoxic therapies. The severity of ICI-M is heterogeneous and can now be stratified using the presence of active thymoma, cardiomuscular symptoms, low QRS-voltage, left ventricular ejection fraction

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisImmune Checkpoint InhibitorsHumansAnimalsCardiotoxicity

Stichwörter der Autor:innen

cardio-oncologymyasthenia-gravismyocarditismyositispharmacology

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Sorbonne Université, INSERM, Department of Pharmacology, CIC-2503, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

ORCID-Profile: Joe-Elie Salem

Zitieren

APA

Salem, J. E. (2026). Immune Checkpoint Inhibitor Myocarditis and Myotoxicity. Circulation, 154(9), 863-871. https://doi.org/10.1161/circulationaha.126.081201

Vancouver

Salem JE. Immune Checkpoint Inhibitor Myocarditis and Myotoxicity. Circulation. 2026;154(9):863-871. doi:10.1161/circulationaha.126.081201

BibTeX
@article{Salem2026,
  author = {Salem, Joe-Elie},
  title = {Immune Checkpoint Inhibitor Myocarditis and Myotoxicity},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {9},
  pages = {863--871},
  doi = {10.1161/circulationaha.126.081201}
}
Kostenlos starten →